Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019
• Clinical characteristics and immune-inflammatory parameters were compared between non-severe and severe patients with coronavirus disease 2019 (COVID-19).• High level of interleukin-6 (IL-6), C-reactive protein (CRP) and hypertension were independent predictors for the severity of COVID-19.• IL-6...
Saved in:
Published in | International journal of infectious diseases Vol. 95; pp. 332 - 339 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Canada
Elsevier Ltd
01.06.2020
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases Elsevier |
Subjects | |
Online Access | Get full text |
ISSN | 1201-9712 1878-3511 1878-3511 |
DOI | 10.1016/j.ijid.2020.04.041 |
Cover
Loading…
Abstract | • Clinical characteristics and immune-inflammatory parameters were compared between non-severe and severe patients with coronavirus disease 2019 (COVID-19).• High level of interleukin-6 (IL-6), C-reactive protein (CRP) and hypertension were independent predictors for the severity of COVID-19.• IL-6 has the highest predictive value among other single immune-inflammatory parameters. The risk model based on IL-6, CRP and hypertension enlarged the predictability.• The dynamic change of IL-6 in the severe cases were parallel to the amelioration of this disease, implied a potential value for monitoring the process of severe cases.
To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19).
127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value.
Of 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease.
Our study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases. |
---|---|
AbstractList | • Clinical characteristics and immune-inflammatory parameters were compared between non-severe and severe patients with coronavirus disease 2019 (COVID-19).• High level of interleukin-6 (IL-6), C-reactive protein (CRP) and hypertension were independent predictors for the severity of COVID-19.• IL-6 has the highest predictive value among other single immune-inflammatory parameters. The risk model based on IL-6, CRP and hypertension enlarged the predictability.• The dynamic change of IL-6 in the severe cases were parallel to the amelioration of this disease, implied a potential value for monitoring the process of severe cases.
To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19).
127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value.
Of 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease.
Our study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases. To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19).OBJECTIVETo explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19).127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value.METHODS127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value.Of 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease.RESULTSOf 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease.Our study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases.CONCLUSIONOur study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases. • Clinical characteristics and immune-inflammatory parameters were compared between non-severe and severe patients with coronavirus disease 2019 (COVID-19). • High level of interleukin-6 (IL-6), C-reactive protein (CRP) and hypertension were independent predictors for the severity of COVID-19. • IL-6 has the highest predictive value among other single immune-inflammatory parameters. The risk model based on IL-6, CRP and hypertension enlarged the predictability. • The dynamic change of IL-6 in the severe cases were parallel to the amelioration of this disease, implied a potential value for monitoring the process of severe cases. Objective: To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19). Methods: 127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value. Results: Of 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease. Conclusion: Our study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases. To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19). 127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value. Of 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease. Our study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases. |
Author | Cai, Ting Zhu, Zhe Gao, Guosheng Huang, Zuoan Lou, Kehong Hua, Xin Fan, Lingyan |
Author_xml | – sequence: 1 givenname: Zhe surname: Zhu fullname: Zhu, Zhe email: zhuzhemcgrady@163.com organization: Department of Blood Transfusion, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, PR China – sequence: 2 givenname: Ting surname: Cai fullname: Cai, Ting email: caiting@nbu.edu.cn organization: Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, PR China – sequence: 3 givenname: Lingyan surname: Fan fullname: Fan, Lingyan email: lingyan@163.com organization: Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, PR China – sequence: 4 givenname: Kehong surname: Lou fullname: Lou, Kehong email: 516616952@qq.com organization: Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, PR China – sequence: 5 givenname: Xin surname: Hua fullname: Hua, Xin email: 619223610@qq.com organization: Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, PR China – sequence: 6 givenname: Zuoan surname: Huang fullname: Huang, Zuoan email: huangzuoannb@163.com organization: Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, PR China – sequence: 7 givenname: Guosheng surname: Gao fullname: Gao, Guosheng email: 495926922@qq.com organization: Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, PR China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32334118$$D View this record in MEDLINE/PubMed |
BookMark | eNqFUktr3DAQNiWlebR_oIfiYy_e6mVbKqUQljYJBHppz2IsjRNtbWsryQv77yt3t6HJIYUBDdL3GDTfeXEy-QmL4i0lK0po82GzchtnV4wwsiIiF31RnFHZyorXlJ7knhFaqZay0-I8xg0hRDSNfFWccsa5oFSeFWY9uMkZGModDDOWvi_dOM4TVm7qBxhHSD7syy0EGDFhiGXyJcSIMXf3WEbcYXBpvxCND36CnQtzLK2LCBHLPIF6XbzsYYj45nheFD--fvm-vq5uv13drC9vK9NwmSrbdLYxvWJM9pT2YPqethxtU6uGceyEqhm2TCgOXQuEMEsUxZ6g4lQaSfhFcXPQtR42ehvcCGGvPTj958KHOw0hOTOgNgKMaIDUqq2F7Vols1HHQWVHYe2i9fmgtZ27Ea3BKQUYHok-fpncvb7zO91SVRPCs8D7o0Dwv2aMSY8uGhwGmNDPUTOuhJS8FQv03b9eDyZ_t5QB7AAwwccYsH-AUKKXKOiNXqKglyhoInLRTJJPSMYlSM4v87rheeqnAxXztnYOg47G4WTQuoAm5e90z9M_PqGbY8h-4v5_5N9Vc-Ok |
CitedBy_id | crossref_primary_10_1186_s13018_020_01702_w crossref_primary_10_1002_rmv_2146 crossref_primary_10_1111_ijlh_13412 crossref_primary_10_1186_s40560_021_00531_1 crossref_primary_10_3389_fncel_2021_748136 crossref_primary_10_1590_1414_431x2021e11711 crossref_primary_10_1007_s11897_021_00505_2 crossref_primary_10_1136_bmj_m1328 crossref_primary_10_2147_IDR_S321915 crossref_primary_10_1016_j_ijid_2021_01_059 crossref_primary_10_1093_ajcp_aqaa205 crossref_primary_10_4103_jdmimsu_jdmimsu_230_22 crossref_primary_10_2139_ssrn_3949424 crossref_primary_10_12688_f1000research_132157_1 crossref_primary_10_36106_ijar_3001402 crossref_primary_10_3389_fimmu_2022_978619 crossref_primary_10_3390_vaccines10111818 crossref_primary_10_24293_ijcpml_v29i2_1997 crossref_primary_10_1371_journal_pone_0279935 crossref_primary_10_1016_j_ajem_2021_01_006 crossref_primary_10_1177_1751143720969587 crossref_primary_10_1186_s42269_022_00856_3 crossref_primary_10_3389_fcell_2022_914781 crossref_primary_10_29296_25877305_2024_06_16 crossref_primary_10_1016_j_imu_2021_100564 crossref_primary_10_4103_NJM_NJM_142_20 crossref_primary_10_1186_s12876_022_02132_0 crossref_primary_10_5005_jp_journals_10006_2010 crossref_primary_10_1016_j_intimp_2023_110626 crossref_primary_10_36425_rehab104997 crossref_primary_10_1007_s12250_021_00425_4 crossref_primary_10_1002_rmv_70026 crossref_primary_10_1016_j_medine_2020_12_001 crossref_primary_10_46235_1028_7221_13945_IAB crossref_primary_10_29328_journal_jprr_1001019 crossref_primary_10_1038_s41392_021_00849_0 crossref_primary_10_4103_abr_abr_257_23 crossref_primary_10_3389_fmed_2021_588013 crossref_primary_10_1002_jmv_26346 crossref_primary_10_3389_fpsyt_2023_1241190 crossref_primary_10_1111_1744_9987_14108 crossref_primary_10_4103_bbrj_bbrj_188_20 crossref_primary_10_1371_journal_pone_0241541 crossref_primary_10_1136_bmjopen_2020_044640 crossref_primary_10_1016_j_carbpol_2022_120350 crossref_primary_10_1177_08850666211045626 crossref_primary_10_3390_life11030182 crossref_primary_10_3748_wjg_v27_i24_3516 crossref_primary_10_3390_jcm11041011 crossref_primary_10_3390_covid3060059 crossref_primary_10_1089_jir_2022_0029 crossref_primary_10_2174_1874285802115010077 crossref_primary_10_1002_jja2_12838 crossref_primary_10_1016_j_eclinm_2020_100527 crossref_primary_10_1055_s_0043_1772595 crossref_primary_10_3389_fmed_2022_988666 crossref_primary_10_4103_cmrp_cmrp_113_22 crossref_primary_10_1007_s10875_020_00821_7 crossref_primary_10_2147_IJGM_S355083 crossref_primary_10_1017_S0950268821000078 crossref_primary_10_1002_med_21997 crossref_primary_10_3390_brainsci12020250 crossref_primary_10_1080_14740338_2021_1946513 crossref_primary_10_3389_fmed_2020_00301 crossref_primary_10_1002_ejsc_12262 crossref_primary_10_1186_s12879_021_06623_5 crossref_primary_10_1016_j_ajem_2020_10_022 crossref_primary_10_1038_s41598_024_70172_5 crossref_primary_10_1016_j_cca_2023_117586 crossref_primary_10_1016_j_jelectrocard_2021_01_012 crossref_primary_10_3390_jcm10184142 crossref_primary_10_3390_life13010186 crossref_primary_10_3389_fphar_2022_973587 crossref_primary_10_7861_clinmed_21_2_s36 crossref_primary_10_3390_diagnostics11081327 crossref_primary_10_1016_j_abst_2022_10_001 crossref_primary_10_1097_MD_0000000000031138 crossref_primary_10_4103_ajim_ajim_77_21 crossref_primary_10_1128_mBio_01372_21 crossref_primary_10_3390_medicina58020144 crossref_primary_10_1016_j_medin_2020_07_007 crossref_primary_10_1007_s12291_020_00897_3 crossref_primary_10_3389_fmed_2020_00431 crossref_primary_10_1016_j_eclinm_2020_100550 crossref_primary_10_1016_j_cegh_2021_100727 crossref_primary_10_1016_j_heliyon_2021_e06155 crossref_primary_10_12688_f1000research_125115_1 crossref_primary_10_12688_f1000research_125115_2 crossref_primary_10_1371_journal_pone_0253894 crossref_primary_10_3389_fimmu_2022_986950 crossref_primary_10_1002_clc_23465 crossref_primary_10_1016_j_heliyon_2024_e27251 crossref_primary_10_1016_j_intimp_2022_109428 crossref_primary_10_1507_endocrj_EJ20_0443 crossref_primary_10_1007_s13318_020_00668_8 crossref_primary_10_1016_j_cyto_2023_156287 crossref_primary_10_3389_fimmu_2020_01518 crossref_primary_10_3389_fimmu_2021_593595 crossref_primary_10_1016_j_autneu_2021_102903 crossref_primary_10_4103_ecdt_ecdt_2_22 crossref_primary_10_18772_26180197_2020_v2n2a3 crossref_primary_10_2196_23390 crossref_primary_10_1136_postgradmedj_2021_139939 crossref_primary_10_1002_jcb_30683 crossref_primary_10_3389_fphar_2022_973246 crossref_primary_10_7554_eLife_79946 crossref_primary_10_1002_iid3_471 crossref_primary_10_1016_j_jaci_2020_05_008 crossref_primary_10_1016_j_mayocpiqo_2021_01_009 crossref_primary_10_3390_ijerph20032146 crossref_primary_10_1016_j_freeradbiomed_2025_01_015 crossref_primary_10_3390_jcm10091924 crossref_primary_10_1016_j_jaip_2020_06_039 crossref_primary_10_1002_bies_202000094 crossref_primary_10_1371_journal_pbio_3001109 crossref_primary_10_7759_cureus_57336 crossref_primary_10_1093_trstmh_trad012 crossref_primary_10_1111_iji_12605 crossref_primary_10_1002_rmv_2195 crossref_primary_10_1016_j_bios_2024_116618 crossref_primary_10_1016_j_ijid_2020_10_003 crossref_primary_10_4103_jcsr_jcsr_66_22 crossref_primary_10_1016_j_arcmed_2021_06_004 crossref_primary_10_1002_jcla_24881 crossref_primary_10_3389_fphar_2022_802228 crossref_primary_10_1177_00045632211011194 crossref_primary_10_1177_10760296211010973 crossref_primary_10_1155_2023_7258585 crossref_primary_10_1515_tjb_2020_0624 crossref_primary_10_12688_f1000research_146814_1 crossref_primary_10_1155_2022_7920915 crossref_primary_10_3389_fphar_2022_853496 crossref_primary_10_3389_fimmu_2023_1197467 crossref_primary_10_1080_19390211_2022_2075072 crossref_primary_10_3389_fimmu_2020_603389 crossref_primary_10_1016_j_prp_2021_153610 crossref_primary_10_1002_jmv_27800 crossref_primary_10_1186_s12964_021_00754_7 crossref_primary_10_1038_s41598_023_37846_y crossref_primary_10_1002_jmv_26836 crossref_primary_10_1080_08039488_2022_2116106 crossref_primary_10_14412_1995_4484_2020_245_261 crossref_primary_10_4103_ijpm_ijpm_658_21 crossref_primary_10_1016_j_biopha_2020_110698 crossref_primary_10_1016_j_jaip_2020_10_043 crossref_primary_10_1002_jmv_26166 crossref_primary_10_1080_08820139_2020_1773850 crossref_primary_10_1007_s00421_021_04668_7 crossref_primary_10_3233_THC_220321 crossref_primary_10_3390_v15091925 crossref_primary_10_3390_life14020163 crossref_primary_10_1038_s41421_021_00305_x crossref_primary_10_1016_j_clim_2020_108615 crossref_primary_10_1017_S1047951124000283 crossref_primary_10_31363_2313_7053_2024_794 crossref_primary_10_4103_jpbs_JPBS_655_20 crossref_primary_10_1007_s10157_021_02101_z crossref_primary_10_1016_j_amjoto_2020_102796 crossref_primary_10_1371_journal_ppat_1009865 crossref_primary_10_1186_s12911_020_01338_0 crossref_primary_10_3389_fmed_2021_699607 crossref_primary_10_1177_1753466620933508 crossref_primary_10_1007_s11739_021_02750_8 crossref_primary_10_26442_00403660_2022_01_201323 crossref_primary_10_3390_v14061188 crossref_primary_10_1186_s41983_023_00784_7 crossref_primary_10_1016_j_cyto_2021_155428 crossref_primary_10_3889_oamjms_2022_8545 crossref_primary_10_1210_clinem_dgad284 crossref_primary_10_1080_17843286_2020_1822078 crossref_primary_10_1038_s41538_024_00261_2 crossref_primary_10_3389_fmed_2023_1252556 crossref_primary_10_36106_ijsr_7525405 crossref_primary_10_1016_j_mehy_2020_110208 crossref_primary_10_1093_ajcn_nqab426 crossref_primary_10_36660_ijcs_20200150 crossref_primary_10_1016_j_bvth_2024_100034 crossref_primary_10_1016_j_smim_2021_101508 crossref_primary_10_1016_j_freeradbiomed_2021_01_044 crossref_primary_10_3390_jcm10020297 crossref_primary_10_3390_vaccines10081233 crossref_primary_10_18410_jebmh_2021_466 crossref_primary_10_36106_ijsr_8404512 crossref_primary_10_1080_02770903_2021_1888116 crossref_primary_10_3390_vaccines10101764 crossref_primary_10_1093_ndt_gfad111 crossref_primary_10_1007_s11596_021_2320_7 crossref_primary_10_1186_s12879_021_05847_9 crossref_primary_10_1007_s10787_022_01047_2 crossref_primary_10_1186_s13293_021_00363_6 crossref_primary_10_1007_s10238_021_00708_w crossref_primary_10_1007_s12519_020_00368_y crossref_primary_10_2478_abm_2022_0020 crossref_primary_10_1016_j_ajem_2020_05_022 crossref_primary_10_1177_0885066620969132 crossref_primary_10_1038_s41598_024_71569_y crossref_primary_10_1038_s41598_021_92885_7 crossref_primary_10_1016_j_ajem_2020_09_018 crossref_primary_10_3390_biomedinformatics3020023 crossref_primary_10_3390_diagnostics12081847 crossref_primary_10_1002_ams2_683 crossref_primary_10_1007_s12192_023_01330_3 crossref_primary_10_17116_oftalma2021137052331 crossref_primary_10_1002_jcla_23911 crossref_primary_10_1016_j_intimp_2021_108255 crossref_primary_10_3390_pathogens11020195 crossref_primary_10_1002_rmv_2221 crossref_primary_10_1007_s00421_022_05126_8 crossref_primary_10_3390_ijerph19031172 crossref_primary_10_1002_edm2_338 crossref_primary_10_1002_hsr2_868 crossref_primary_10_1371_journal_pone_0302977 crossref_primary_10_33713_egetbd_1167278 crossref_primary_10_3390_pathogens10091105 crossref_primary_10_1177_20503121221108613 crossref_primary_10_1177_11772719221106600 crossref_primary_10_1007_s12016_021_08908_8 crossref_primary_10_1002_jmv_27297 crossref_primary_10_2139_ssrn_3951144 crossref_primary_10_3389_fcell_2021_578825 crossref_primary_10_2174_1381612827666210311141512 crossref_primary_10_7759_cureus_15235 crossref_primary_10_1016_j_cyto_2021_155455 crossref_primary_10_3390_biomedicines12092055 crossref_primary_10_1515_biol_2022_0502 crossref_primary_10_3389_fneur_2020_01031 crossref_primary_10_3390_jcm11102945 crossref_primary_10_35366_104875 crossref_primary_10_1016_j_ejphar_2023_176061 crossref_primary_10_2298_MPNS2312344B crossref_primary_10_1017_S0950268821002545 crossref_primary_10_1155_2022_4461647 crossref_primary_10_12688_f1000research_74023_1 crossref_primary_10_2174_1871529X21666211201110007 crossref_primary_10_36740_WLek202104144 crossref_primary_10_12688_f1000research_74023_2 crossref_primary_10_1038_s41598_024_81225_0 crossref_primary_10_1155_2022_2755246 crossref_primary_10_1016_j_intimp_2021_107828 crossref_primary_10_1002_jmv_26411 crossref_primary_10_1186_s12879_023_08816_6 crossref_primary_10_4103_cjhr_cjhr_87_24 crossref_primary_10_4103_jmms_jmms_3_21 crossref_primary_10_1155_2022_4161235 crossref_primary_10_3389_fbioe_2020_00916 crossref_primary_10_1016_j_cyto_2023_156445 crossref_primary_10_1016_j_bbadis_2024_167472 crossref_primary_10_18087_cardio_2020_6_n1226 crossref_primary_10_1056_NEJMra2026131 crossref_primary_10_4103_ejh_ejh_3_22 crossref_primary_10_3389_fimmu_2021_666223 crossref_primary_10_4103_jpbs_jpbs_88_23 crossref_primary_10_1007_s11655_021_3350_5 crossref_primary_10_1371_journal_pone_0271807 crossref_primary_10_3233_CH_200978 crossref_primary_10_1186_s12879_021_06457_1 crossref_primary_10_1002_agm2_12149 crossref_primary_10_1371_journal_pone_0283469 crossref_primary_10_4103_jfmpc_jfmpc_2196_20 crossref_primary_10_1038_s41392_021_00764_4 crossref_primary_10_3390_ijerph18105342 crossref_primary_10_3390_jcm11082235 crossref_primary_10_1177_1060028021999473 crossref_primary_10_1186_s12879_020_05619_x crossref_primary_10_4103_jodp_jodp_46_23 crossref_primary_10_1016_j_cytogfr_2022_07_002 crossref_primary_10_53730_ijhs_v5nS1_15129 crossref_primary_10_1002_jmv_29935 crossref_primary_10_1136_bcr_2020_236720 crossref_primary_10_3389_fneur_2021_657004 crossref_primary_10_3389_fmed_2021_780750 crossref_primary_10_3389_fpls_2022_780257 crossref_primary_10_1177_87551225221104323 crossref_primary_10_17749_2313_7347_ob_gyn_rep_2021_249 crossref_primary_10_3389_fimmu_2021_742941 crossref_primary_10_1186_s12985_024_02400_3 crossref_primary_10_1016_j_jpsychires_2021_07_027 crossref_primary_10_4102_ajlm_v9i1_1282 |
Cites_doi | 10.1038/s41579-018-0118-9 10.1007/s00259-020-04735-9 10.1101/2020.03.01.20029769 10.1016/S0140-6736(20)30154-9 10.1038/nri3552 10.1038/nm1267 10.1016/j.ijid.2020.03.004 10.1089/jir.2019.0085 10.1101/2020.02.07.937862 10.1101/2020.02.12.945576 10.3390/jcm9010267 10.1038/cmi.2015.74 10.1002/jmv.25748 10.1084/jem.20171773 10.21203/rs.3.rs-19346/v1 10.2217/imt-2016-0020 10.1007/s00281-017-0639-8 10.1101/2020.02.10.20021584 10.1007/s00281-017-0629-x 10.1074/jbc.M210429200 10.1101/2020.02.16.20023671 10.1093/cid/ciaa272 10.3201/eid1005.030640 10.1001/jama.2020.1585 10.1101/2020.01.22.914952 |
ContentType | Journal Article |
Copyright | 2020 The Author(s) Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. 2020 The Author(s) 2020 |
Copyright_xml | – notice: 2020 The Author(s) – notice: Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. – notice: 2020 The Author(s) 2020 |
DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1016/j.ijid.2020.04.041 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ: Directory of Open Access Journal (DOAJ) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Public Health |
EISSN | 1878-3511 |
EndPage | 339 |
ExternalDocumentID | oai_doaj_org_article_c4ac46a059754db7983edb3a91734dd0 PMC7195003 32334118 10_1016_j_ijid_2020_04_041 S1201971220302575 |
Genre | Journal Article |
GroupedDBID | --- --K .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 29J 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 7X7 88E 8C1 8FI 8FJ 8FQ 8R4 8R5 AAEDW AAFWJ AAIKJ AALRI AAQFI AAQXK AARKO AAXUO AAYWO ABBQC ABFRF ABMAC ABUWG ABWVN ACGFO ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFJKZ AFKRA AFPKN AFPUW AFRHN AFTJW AGEKW AGHFR AGQPQ AGYEJ AHMBA AIGII AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN BAWUL BCNDV BENPR BPHCQ BR6 BVXVI CCPQU CS3 DIK DU5 DWQXO E3Z EBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FNPLU FYUFA G-Q GBLVA GROUPED_DOAJ GX1 HMCUK HVGLF HZ~ IHE IXB J1W KQ8 M1P M3C M3G M41 MO0 N9A O-L O9- OD- OK1 OO. OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO Q2X Q38 QTD R2- ROL RPZ RWL RXW SDF SDG SEL SES SEW SSZ TAE UKHRP UNMZH Z5R 0SF 3V. 6I. AACTN AAFTH ABVKL AFCTW NCXOZ RIG AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c638t-d6bd6cf9228f11facff173ed659623eb4952e72493ab7a002d091ef0e9318c803 |
IEDL.DBID | IXB |
ISSN | 1201-9712 1878-3511 |
IngestDate | Wed Aug 27 01:30:17 EDT 2025 Thu Aug 21 14:03:36 EDT 2025 Thu Jul 10 22:32:10 EDT 2025 Wed Feb 19 02:11:53 EST 2025 Tue Jul 01 04:29:52 EDT 2025 Thu Apr 24 22:51:12 EDT 2025 Fri Feb 23 02:48:03 EST 2024 Tue Aug 26 16:33:04 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | COVID-19 SARS-CoV-2 Cytokine storm IL-6 Immune-inflammatory parameters |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c638t-d6bd6cf9228f11facff173ed659623eb4952e72493ab7a002d091ef0e9318c803 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Contributed equally. |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S1201971220302575 |
PMID | 32334118 |
PQID | 2394883743 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_c4ac46a059754db7983edb3a91734dd0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7195003 proquest_miscellaneous_2394883743 pubmed_primary_32334118 crossref_primary_10_1016_j_ijid_2020_04_041 crossref_citationtrail_10_1016_j_ijid_2020_04_041 elsevier_sciencedirect_doi_10_1016_j_ijid_2020_04_041 elsevier_clinicalkey_doi_10_1016_j_ijid_2020_04_041 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2020-06-01 |
PublicationDateYYYYMMDD | 2020-06-01 |
PublicationDate_xml | – month: 06 year: 2020 text: 2020-06-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Canada |
PublicationPlace_xml | – name: Canada |
PublicationTitle | International journal of infectious diseases |
PublicationTitleAlternate | Int J Infect Dis |
PublicationYear | 2020 |
Publisher | Elsevier Ltd The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases Elsevier |
Publisher_xml | – name: Elsevier Ltd – name: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases – name: Elsevier |
References | Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al., Severe acute respiratory syndrome-related coronavirus: The species and its viruses–a statement of the Coronavirus Stu***dy Gro***up. bioRxiv 2020. doi: https://doi.org/10.1101/2020.02.07.937862. Chousterman, Swirski, Weber (bib0030) 2017; 39 Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al., Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv 2020. doi:https://doi.org/10.1101/2020.01.22.914952. Peng Y, Meng K, Guan H, Leng L, Zhu R, Wang B, et al., Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Chinese Journal of Cardiology 2020. doi: 10.3760/cma.j.cn112148-20200220-00105. Chen, Zhou, Dong, Qu, Gong, Han (bib0020) 2020; 395 Chen, Thai, Zhao, Ho, DeSouza, Wu (bib0025) 2003; 278 Wang, Sheng, Fang, Chen, Wang, Yu (bib0120) 2004; 10 Liu, Zhou, Yang (bib0075) 2016; 13 Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis 2020. doi: 10.1016/j.ijid.2020.03.004. Hotchkiss, Monneret, Payen (bib0055) 2013; 13 Zhou Y, Fu B, Zheng X, Wang D, Zhao C, qi Y, et al., Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv 2020. doi: https://doi.org/10.1101/2020.02.12.945576. Chen C, Chen C, Yan J, Zhou N, Zhao J, Wang D. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Chinese Journal of Cardiology. doi: 10.3760/cma.j.cn112148-20200225-00123. Chan, Yuan, Kok, To, Chu, Yang (bib0005) 2020; 395 Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol 2020. doi: 10.1002/jmv.25748. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al., The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. medRxiv 2020. doi: https://doi.org/10.1101/2020.03.01.20029769. Channappanavar, Perlman (bib0010) 2017; 39 Guo, Cao, Hong, Tan, Chen, Jin (bib0045) 2020; 7 Xu, Yu, Qu, Zhang, Jiang, Huang (bib0140) 2020; 47 Kuba, Imai, Rao, Gao, Guo, Guan (bib0060) 2005; 11 Povlsen, Grimm, Wehland, Infanger, Kruger (bib0095) 2020; 9 Tanaka, Narazaki, Kishimoto (bib0105) 2016; 8 Gupta, Khan, Singh (bib0050) 2020; 40 Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al., Neutrophil-to-Lymphocyte Ratio Predicts Severe illness Patients with 2019 Novel Coronavirus in the Early Stage. medRxiv 2020. doi: https://doi.org/10.1101/2020.02.10.20021584. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020. doi: 10.1001/jama.2020.1585. Shi Y, Ou J, Chen X, Tan M, Li F, Liu Y. Expressions of multiple inflammation markers in the patients with 2019 novel coronavirus pneumonia and their clinical values. Chinese Journal of Laboratory Medicine 2020. doi: 10.3760/cma.j.cn114452-20200214-00073. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al., Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv 2020. doi: https://doi.org/10.1101/2020.02.16.20023671. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa272. Wang C, Xie J, Zhao L, Fe X, Zhang H, Tan Y, et al., Aveolar Macrophage Activation and Cytokine Storm in the Pathogenesis of Severe COVID-19. 25 March 2020, PREPRINT (Version 1) available at Research Square [+https://doi.org/10.21203/rs.3.rs-19346/v1+]. Cui, Li, Shi (bib0035) 2019; 17 Norlander, Madhur, Harrison (bib0085) 2018; 215 10.1016/j.ijid.2020.04.041_bib0100 10.1016/j.ijid.2020.04.041_bib0145 10.1016/j.ijid.2020.04.041_bib0125 Chousterman (10.1016/j.ijid.2020.04.041_bib0030) 2017; 39 Chen (10.1016/j.ijid.2020.04.041_bib0020) 2020; 395 Chan (10.1016/j.ijid.2020.04.041_bib0005) 2020; 395 Kuba (10.1016/j.ijid.2020.04.041_bib0060) 2005; 11 Norlander (10.1016/j.ijid.2020.04.041_bib0085) 2018; 215 Guo (10.1016/j.ijid.2020.04.041_bib0045) 2020; 7 10.1016/j.ijid.2020.04.041_bib0090 10.1016/j.ijid.2020.04.041_bib0070 10.1016/j.ijid.2020.04.041_bib0150 10.1016/j.ijid.2020.04.041_bib0130 10.1016/j.ijid.2020.04.041_bib0110 10.1016/j.ijid.2020.04.041_bib0135 10.1016/j.ijid.2020.04.041_bib0015 Povlsen (10.1016/j.ijid.2020.04.041_bib0095) 2020; 9 10.1016/j.ijid.2020.04.041_bib0115 Wang (10.1016/j.ijid.2020.04.041_bib0120) 2004; 10 Hotchkiss (10.1016/j.ijid.2020.04.041_bib0055) 2013; 13 Gupta (10.1016/j.ijid.2020.04.041_bib0050) 2020; 40 Chen (10.1016/j.ijid.2020.04.041_bib0025) 2003; 278 Xu (10.1016/j.ijid.2020.04.041_bib0140) 2020; 47 Tanaka (10.1016/j.ijid.2020.04.041_bib0105) 2016; 8 Cui (10.1016/j.ijid.2020.04.041_bib0035) 2019; 17 Channappanavar (10.1016/j.ijid.2020.04.041_bib0010) 2017; 39 Liu (10.1016/j.ijid.2020.04.041_bib0075) 2016; 13 10.1016/j.ijid.2020.04.041_bib0080 10.1016/j.ijid.2020.04.041_bib0040 10.1016/j.ijid.2020.04.041_bib0065 |
References_xml | – reference: Zhou Y, Fu B, Zheng X, Wang D, Zhao C, qi Y, et al., Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv 2020. doi: https://doi.org/10.1101/2020.02.12.945576. – reference: Peng Y, Meng K, Guan H, Leng L, Zhu R, Wang B, et al., Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Chinese Journal of Cardiology 2020. doi: 10.3760/cma.j.cn112148-20200220-00105. – reference: Shi Y, Ou J, Chen X, Tan M, Li F, Liu Y. Expressions of multiple inflammation markers in the patients with 2019 novel coronavirus pneumonia and their clinical values. Chinese Journal of Laboratory Medicine 2020. doi: 10.3760/cma.j.cn114452-20200214-00073. – volume: 11 start-page: 875 year: 2005 end-page: 879 ident: bib0060 article-title: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury publication-title: Nat Med – volume: 40 start-page: 19 year: 2020 end-page: 23 ident: bib0050 article-title: Constitutive Inflammatory Cytokine Storm: A Major Threat to Human Health publication-title: J Interferon Cytokine Res – reference: Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol 2020. doi: 10.1002/jmv.25748. – reference: Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa272. – reference: Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis 2020. doi: 10.1016/j.ijid.2020.03.004. – volume: 47 start-page: 1275 year: 2020 end-page: 1280 ident: bib0140 article-title: Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2 publication-title: Eur J Nucl Med Mol Imaging – reference: Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020. doi: 10.1001/jama.2020.1585. – volume: 10 start-page: 818 year: 2004 end-page: 824 ident: bib0120 article-title: Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients publication-title: Emerg Infect Dis – reference: Wang C, Xie J, Zhao L, Fe X, Zhang H, Tan Y, et al., Aveolar Macrophage Activation and Cytokine Storm in the Pathogenesis of Severe COVID-19. 25 March 2020, PREPRINT (Version 1) available at Research Square [+https://doi.org/10.21203/rs.3.rs-19346/v1+]. – reference: Chen C, Chen C, Yan J, Zhou N, Zhao J, Wang D. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Chinese Journal of Cardiology. doi: 10.3760/cma.j.cn112148-20200225-00123. – volume: 395 start-page: 514 year: 2020 end-page: 523 ident: bib0005 article-title: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster publication-title: Lancet – volume: 13 start-page: 3 year: 2016 end-page: 10 ident: bib0075 article-title: The cytokine storm of severe influenza and development of immunomodulatory therapy publication-title: Cell Mol Immunol – volume: 8 start-page: 959 year: 2016 end-page: 970 ident: bib0105 article-title: Immunotherapeutic implications of IL-6 blockade for cytokine storm publication-title: Immunotherapy – volume: 13 start-page: 862 year: 2013 end-page: 874 ident: bib0055 article-title: Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy publication-title: Nat Rev Immunol – volume: 395 start-page: 507 year: 2020 end-page: 513 ident: bib0020 article-title: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan publication-title: China: a descriptive study. Lancet – reference: Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al., Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv 2020. doi: https://doi.org/10.1101/2020.02.16.20023671. – volume: 7 start-page: 11 year: 2020 ident: bib0045 article-title: The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status publication-title: Mil Med Res – volume: 9 start-page: 267 year: 2020 ident: bib0095 article-title: The Vasoactive Mas Receptor in Essential Hypertension publication-title: J Clin Med – reference: Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al., Severe acute respiratory syndrome-related coronavirus: The species and its viruses–a statement of the Coronavirus Stu***dy Gro***up. bioRxiv 2020. doi: https://doi.org/10.1101/2020.02.07.937862. – volume: 39 start-page: 529 year: 2017 end-page: 539 ident: bib0010 article-title: Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology publication-title: Semin Immunopathol – volume: 278 start-page: 17036 year: 2003 end-page: 17043 ident: bib0025 article-title: Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop publication-title: J Biol Chem – volume: 215 start-page: 21 year: 2018 end-page: 33 ident: bib0085 article-title: The immunology of hypertension publication-title: J Exp Med – reference: Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al., Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv 2020. doi:https://doi.org/10.1101/2020.01.22.914952. – reference: Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al., Neutrophil-to-Lymphocyte Ratio Predicts Severe illness Patients with 2019 Novel Coronavirus in the Early Stage. medRxiv 2020. doi: https://doi.org/10.1101/2020.02.10.20021584. – reference: Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al., The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. medRxiv 2020. doi: https://doi.org/10.1101/2020.03.01.20029769. – volume: 17 start-page: 181 year: 2019 end-page: 192 ident: bib0035 article-title: Origin and evolution of pathogenic coronaviruses publication-title: Nat Rev Microbiol – volume: 39 start-page: 517 year: 2017 end-page: 528 ident: bib0030 article-title: Cytokine storm and sepsis disease pathogenesis publication-title: Semin Immunopathol – volume: 17 start-page: 181 issue: 3 year: 2019 ident: 10.1016/j.ijid.2020.04.041_bib0035 article-title: Origin and evolution of pathogenic coronaviruses publication-title: Nat Rev Microbiol doi: 10.1038/s41579-018-0118-9 – ident: 10.1016/j.ijid.2020.04.041_bib0015 – volume: 7 start-page: 11 issue: 1 year: 2020 ident: 10.1016/j.ijid.2020.04.041_bib0045 article-title: The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status publication-title: Mil Med Res – volume: 47 start-page: 1275 issue: 5 year: 2020 ident: 10.1016/j.ijid.2020.04.041_bib0140 article-title: Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-020-04735-9 – ident: 10.1016/j.ijid.2020.04.041_bib0080 doi: 10.1101/2020.03.01.20029769 – ident: 10.1016/j.ijid.2020.04.041_bib0090 – volume: 395 start-page: 514 issue: 10223 year: 2020 ident: 10.1016/j.ijid.2020.04.041_bib0005 article-title: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster publication-title: Lancet doi: 10.1016/S0140-6736(20)30154-9 – volume: 13 start-page: 862 issue: 12 year: 2013 ident: 10.1016/j.ijid.2020.04.041_bib0055 article-title: Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy publication-title: Nat Rev Immunol doi: 10.1038/nri3552 – volume: 11 start-page: 875 issue: 8 year: 2005 ident: 10.1016/j.ijid.2020.04.041_bib0060 article-title: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury publication-title: Nat Med doi: 10.1038/nm1267 – ident: 10.1016/j.ijid.2020.04.041_bib0135 doi: 10.1016/j.ijid.2020.03.004 – volume: 395 start-page: 507 issue: 10223 year: 2020 ident: 10.1016/j.ijid.2020.04.041_bib0020 article-title: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan publication-title: China: a descriptive study. Lancet – volume: 40 start-page: 19 issue: 1 year: 2020 ident: 10.1016/j.ijid.2020.04.041_bib0050 article-title: Constitutive Inflammatory Cytokine Storm: A Major Threat to Human Health publication-title: J Interferon Cytokine Res doi: 10.1089/jir.2019.0085 – ident: 10.1016/j.ijid.2020.04.041_bib0040 doi: 10.1101/2020.02.07.937862 – ident: 10.1016/j.ijid.2020.04.041_bib0150 doi: 10.1101/2020.02.12.945576 – volume: 9 start-page: 267 issue: 1 year: 2020 ident: 10.1016/j.ijid.2020.04.041_bib0095 article-title: The Vasoactive Mas Receptor in Essential Hypertension publication-title: J Clin Med doi: 10.3390/jcm9010267 – volume: 13 start-page: 3 issue: 1 year: 2016 ident: 10.1016/j.ijid.2020.04.041_bib0075 article-title: The cytokine storm of severe influenza and development of immunomodulatory therapy publication-title: Cell Mol Immunol doi: 10.1038/cmi.2015.74 – ident: 10.1016/j.ijid.2020.04.041_bib0125 doi: 10.1002/jmv.25748 – volume: 215 start-page: 21 issue: 1 year: 2018 ident: 10.1016/j.ijid.2020.04.041_bib0085 article-title: The immunology of hypertension publication-title: J Exp Med doi: 10.1084/jem.20171773 – ident: 10.1016/j.ijid.2020.04.041_bib0110 doi: 10.21203/rs.3.rs-19346/v1 – volume: 8 start-page: 959 issue: 8 year: 2016 ident: 10.1016/j.ijid.2020.04.041_bib0105 article-title: Immunotherapeutic implications of IL-6 blockade for cytokine storm publication-title: Immunotherapy doi: 10.2217/imt-2016-0020 – volume: 39 start-page: 517 issue: 5 year: 2017 ident: 10.1016/j.ijid.2020.04.041_bib0030 article-title: Cytokine storm and sepsis disease pathogenesis publication-title: Semin Immunopathol doi: 10.1007/s00281-017-0639-8 – ident: 10.1016/j.ijid.2020.04.041_bib0070 doi: 10.1101/2020.02.10.20021584 – volume: 39 start-page: 529 issue: 5 year: 2017 ident: 10.1016/j.ijid.2020.04.041_bib0010 article-title: Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology publication-title: Semin Immunopathol doi: 10.1007/s00281-017-0629-x – volume: 278 start-page: 17036 issue: 19 year: 2003 ident: 10.1016/j.ijid.2020.04.041_bib0025 article-title: Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop publication-title: J Biol Chem doi: 10.1074/jbc.M210429200 – ident: 10.1016/j.ijid.2020.04.041_bib0065 doi: 10.1101/2020.02.16.20023671 – ident: 10.1016/j.ijid.2020.04.041_bib0130 doi: 10.1093/cid/ciaa272 – volume: 10 start-page: 818 issue: 5 year: 2004 ident: 10.1016/j.ijid.2020.04.041_bib0120 article-title: Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients publication-title: Emerg Infect Dis doi: 10.3201/eid1005.030640 – ident: 10.1016/j.ijid.2020.04.041_bib0115 doi: 10.1001/jama.2020.1585 – ident: 10.1016/j.ijid.2020.04.041_bib0100 – ident: 10.1016/j.ijid.2020.04.041_bib0145 doi: 10.1101/2020.01.22.914952 |
SSID | ssj0004668 |
Score | 2.648697 |
Snippet | • Clinical characteristics and immune-inflammatory parameters were compared between non-severe and severe patients with coronavirus disease 2019 (COVID-19).•... To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19). 127 consecutive hospitalized... To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19).OBJECTIVETo explore the clinical... • Clinical characteristics and immune-inflammatory parameters were compared between non-severe and severe patients with coronavirus disease 2019 (COVID-19). •... Objective: To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19). Methods: 127 consecutive... |
SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 332 |
SubjectTerms | Adult Aged Betacoronavirus C-Reactive Protein - analysis Coronavirus Infections - etiology Coronavirus Infections - immunology COVID-19 Cytokine storm Female Humans Hypertension - complications IL-6 Immune-inflammatory parameters Interleukin-6 - blood Male Middle Aged Pandemics Pneumonia, Viral - etiology Pneumonia, Viral - immunology Risk Factors SARS-CoV-2 Severity of Illness Index |
SummonAdditionalLinks | – databaseName: DOAJ: Directory of Open Access Journal (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Na90wDBejhzEYY-u-si882G2EJbYTJ8dtrJRBd1qhN-NPltLmlb739vdPip3QbNBeBjkldhLLsiVZ0k8AH5zhUdGhu488lrKXTWla7kourDTeurb2dA558qM9PpXfz5qzG6W-KCYswQMnwn1y0jjZGtQCVCO9VX0ngrfCoJkhpPeTtY4ybzamlozIlASH4q3sVc1zukyK7BrOB8II5dUEcirrlUiakPtXkulfzfPvAMobEunoMTzKqiT7nIbwBO6F8RDun2Rn-SE8TEdyLGUaPQWXMUAvGCF8B7aJbKDskFAilyFjXE4Od0Zg4JcUJLNluw0zk1OYoZrI8E8Dlbqjjo6AD8zv4Xq_ZdnHw5AK_TM4Pfr28-txmWsslA5X3q70rfWtiz3nXazraFyMSNjgW6rKI4JF-4kHhTaaMFYZ3D49EjvEKvS4GbiuEs_hYNyM4SWwrml803T4UBlpK2FiUMYL4QmSXnFTQD2TWbsMQE51MC70HGl2rmlqNE2NriRedQEflz5XCX7j1tZfaPaWlgSdPd1AhtKZofRdDFWAmOdez9mpuJ_ii4ZbP90svbLuknSSO_u9n9lL48Imb40Zw2a_1VSzvusEangFvEjstgxMcIHaR90VoFaMuBr5-sk4_JrAwxXV_a3Eq_9BqtfwgIaSIufewMHueh_eoo62s--m5fgHyxI46Q priority: 102 providerName: Directory of Open Access Journals |
Title | Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019 |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1201971220302575 https://dx.doi.org/10.1016/j.ijid.2020.04.041 https://www.ncbi.nlm.nih.gov/pubmed/32334118 https://www.proquest.com/docview/2394883743 https://pubmed.ncbi.nlm.nih.gov/PMC7195003 https://doaj.org/article/c4ac46a059754db7983edb3a91734dd0 |
Volume | 95 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9UwEA7rPoggoutlj5dDBN-knubSpn10F5dFWUF04byFNBftstsu5-Kjv92ZND1sFVYQSqFp0uYymUwyM98Q8sYaHhQeurvAQyZrWWSm5DbjopHGNbZkDs8hzz6Xp-fy47JY7pHj0RcGzSoT7x94euTWKWWRenNx3baLrwzWrloxzoFOgfDQ0VzIKjrxLY9u-EYO7nCQOcPcyXFmsPFqL1pEC-V5hDuVbLI4RQz_yRr1twz6pynljbXp5CF5kIRK-n6o9yOy57sDcvcsqc0PyP3hcI4OPkePiU1ooJcUsb497QNt0U_EZ0BvQCJXUfVOERb8Cs1l1nTTUxPVwxQERgo19Rj0DgtahEAwP9vVdk2Ttodilz0h5ycfvh2fZinaQmZhDm4yVzautKHmvAqMBWNDYEp4V2J8HuEb2Elxr2C3JkyjDDBSB6KGD7mvgS3YKhdPyX7Xd_6Q0KooXFFU8FIZ2eTCBK-ME8IhOL3iZkbY2M3aJihyjIhxqUebswuNQ6NxaHQu4WIz8nZX5noA4rg19xGO3i4ngmjHhH71XScq0lYaK0sDAqYqpGtUXUFzG2FgByukc_mMiHHs9einCpwVPtTe-utiV2pCyf8s93okLw1THPU2pvP9dq0xen1VCZD1ZuTZQG67hgkuQA5h1YyoCSFOWj5907U_Ioy4wgjAuXj-n_V9Qe7h02A295Lsb1Zb_woEtE0zJ3fe_WLzeLwxj7MR7p--VL8BvW47_w |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELZKkQAJIShXOI3EG4o2PhJnH2lFtYVuX2ilfbMcH5CqTao9-vs7kzirBqQiIeUpthMfn8dje-YbQj5bw4PCQ3cXeEjlVOapKbhNuaikcZUtmMNzyPlJMTuT3xf5YoccDL4waFYZZX8v0ztpHd9MYm9Orup68pPB2jVVjHPAKQAvv0fugzZQILSPFvu3nCN7fzjInWL26DnTG3nV5zXShfKs4zuVbLQ6dST-o0XqbyX0T1vKW4vT4VPyJGqV9Gtf8Wdkxzd75ME83pvvkcf96RztnY6eExvpQC8okn172gZao6OITwFwgJHL7u6dIi_4JdrLrOi6paa7H6agMVKoqceod1jQIgeCua6XmxWN1z0U--wFOTv8dnowS2O4hdTCJFynrqhcYcOU8zIwFowNgSnhXYEBeoSvYCvFvYLtmjCVMiBJHegaPmR-CnLBlpl4SXabtvGvCS3z3OV5CYnKyCoTJnhlnBAO2ekVNwlhQzdrG7nIMSTGhR6Mzs41Do3GodGZhIcl5Mu2zFXPxHFn7n0cvW1OZNHuXrTLXzrCSFtprCwMaJgql65S0xKaWwkDW1ghncsSIoax14OjKohW-FB956_zbakRlP9Z7tMALw1zHC9uTOPbzUpj-PqyFKDsJeRVD7dtwwQXoIiwMiFqBMRRy8cpTf274xFXGAI4E2_-s74fycPZ6fxYHx-d_HhLHmFKb0P3juyulxv_HrS1dfWhm403beo8Pg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+value+of+immune-inflammatory+parameters+to+assess+the+severity+of+coronavirus+disease+2019&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Zhu%2C+Zhe&rft.au=Cai%2C+Ting&rft.au=Fan%2C+Lingyan&rft.au=Lou%2C+Kehong&rft.date=2020-06-01&rft.eissn=1878-3511&rft.volume=95&rft.spage=332&rft_id=info:doi/10.1016%2Fj.ijid.2020.04.041&rft_id=info%3Apmid%2F32334118&rft.externalDocID=32334118 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon |